🧬 Aging Wiki

menopause

Properties1
aliasesperimenopause, climacteric, ovarian-aging, reproductive senescence, natural menopause, postmenopause

21 min read

Menopause

Menopause is a physiological life-stage transition, not a disease. It marks the permanent cessation of ovarian follicular activity and menstruation, defined retrospectively after 12 consecutive months of amenorrhea in the absence of other pathological or physiological causes. The median age at the final menstrual period (FMP) in Western populations is approximately 51 years 1.

The ICD-10 N95.x block subdivides the menopausal state: N95.1 (menopausal/female climacteric states — the canonical code used here), N95.0 (premature/postartificial menopause), N95.2 (postmenopausal atrophic vaginitis — see genitourinary-syndrome-menopause), and N95.8/N95.9 (other/unspecified).

Menopause earns a phenotype page in this wiki because it is the earliest and most abrupt organ-system aging event in humans — ovarian function declines and terminates decades before somatic systems fail. The acute and sustained withdrawal of estradiol (and other ovarian hormones) drives a cascade of systemic downstream consequences — accelerated bone loss, cardiovascular risk convergence, vasomotor dysregulation, genitourinary atrophy, skin collagen loss, metabolic redistribution, and altered neuroprotection — making menopause a pivotal upstream node in the female aging trajectory. These downstream consequences are summarized here; canonical detail lives on the linked atomic pages.

STRAW+10 staging system

The Stages of Reproductive Aging Workshop + 10 (STRAW+10) is the international consensus framework for classifying reproductive aging in women 1. It defines seven stages anchored on the final menstrual period (FMP = Stage 0):

StageNameMenstrual patternEndocrine criteria
−5Reproductive: earlyVariable to regularLow FSH, AMH detectable
−4Reproductive: peakRegularLow FSH, AMH detectable
−3bReproductive: lateRegular (no change in length)AMH low, AFC low; FSH unchanged
−3aReproductive: lateSubtle changes (shorter cycles)FSH elevated and variable; AMH low, AFC low
−2Early menopausal transitionVariable cycle length (persistent ≥7-day difference in consecutive cycles)FSH elevated and variable; AMH low
−1Late menopausal transitionAmenorrhea intervals ≥60 days; duration ~1–3 yearsFSH >25 IU/L (random blood draw); estradiol erratic
0FMP — the anchor point——
+1aEarly postmenopause12 months post-FMPFSH rising; estradiol falling (rapid change phase)
+1bEarly postmenopause13–24 months post-FMPFSH still rising; estradiol still falling
+1cEarly postmenopause~3–6 years post-FMP (total early postmenopause ~5–8 yr)FSH and estradiol stabilize; AMH undetectable
+2Late postmenopause~6+ years post-FMP; remaining lifespanStable high FSH, low estradiol; urogenital atrophy increasing

STRAW+10 recognized FSH, inhibin B, AMH, and antral follicle count (AFC) as supportive criteria. The system applies regardless of age, ethnicity, body size, and lifestyle — cross-validated in multiple populations including African, Asian, and South American cohorts 2.

Endocrinology of the transition

Ovarian aging is driven by the progressive depletion of the primordial follicle pool (established in fetal life; non-renewable). As follicle numbers fall:

  1. Inhibin B declines first — granulosa cell–derived inhibin B normally suppresses pituitary FSH; its fall removes negative feedback, causing FSH to rise. This is the earliest detectable endocrine change, preceding menstrual irregularity by years 3.

  2. AMH falls in parallel — granulosa cells of growing follicles secrete anti-Müllerian hormone; AMH tracks follicle pool size more linearly than FSH or estradiol and becomes undetectable well before the FMP. AMH is increasingly used as the most sensitive ovarian reserve marker 4.

  3. FSH rises — the hallmark endocrine signal. STRAW+10 defines Stage −1 (late menopausal transition) as FSH >25 IU/L on a random blood draw, reflecting current international pituitary standards (approximating >40 IU/L in earlier urine-based standards). The cycle day 2–5 endocrine window applies to Stages −3a and −2 when assessing early transition. FSH ≥ 40 IU/L in the menopausal range on two separate samples ≥1 month apart, with ≥4 months amenorrhea before age 40, is used to confirm POI.

  4. Estradiol becomes erratic, then falls — in perimenopause, estradiol can paradoxically spike (anovulatory cycles with high FSH driving multiple follicle recruitment), causing unpredictable symptoms. After the FMP, estradiol stabilizes at low postmenopausal levels (~10–25 pg/mL). The primary residual source is peripheral aromatization of adrenal androgens in adipose tissue.

  5. LH rises — elevated LH is a later-stage marker; the FSH/LH ratio inverts.

  6. Progesterone falls — loss of corpus luteum (anovulatory cycles become predominant in perimenopause) eliminates progesterone’s endometrial protection and neuroactive effects.

Premature ovarian insufficiency (POI): defined as ovarian hypofunction with FSH ≥ 25 IU/L before age 40 5. Prevalence: ~1:10,000 at ages 18–25; ~1:100 at ages 35–40. Causes include idiopathic (~75%), genetic (Turner syndrome, FMR1 premutation, FOXL2 mutations — ~15%), autoimmune, and iatrogenic (chemotherapy, radiation, bilateral oophorectomy).

Early menopause: ages 40–45. Associated with similar but less severe downstream aging acceleration than POI.

Downstream systemic consequences

Estrogen acts on receptors (ERα, ERβ) in virtually every tissue. Sustained withdrawal drives parallel aging accelerations across systems.

Bone: accelerated loss

Estrogen normally suppresses osteoclast activity by promoting osteoclast apoptosis and inhibiting RANKL signaling. Estrogen withdrawal disinhibits osteoclasts, producing a rapid bone remodeling imbalance:

  • Spine and hip BMD loss: ~1–3% per year in the first 5–7 years postmenopause, decelerating to ~0.5–1%/year in late postmenopause 6. Total peri-menopausal bone loss can reach 10–15% of peak bone mass, substantially increasing lifetime fracture risk.
  • Closely linked to osteoporosis; menopause is the dominant driver of postmenopausal osteoporosis.
  • Bone marrow adipose tissue expands as osteoblast/adipocyte lineage balance shifts with estrogen loss 7.
  • Oxidative stress from estrogen deficiency further accelerates osteoclast activity 8.

Cardiovascular: convergence with male risk

Estrogen provides cardioprotection through multiple mechanisms: favorable effects on lipoprotein profiles (↑HDL, ↓LDL-C), endothelial function, arterial elasticity, and insulin sensitivity. These are progressively lost with estrogen withdrawal:

  • LDL-C rises, small dense LDL particles increase; HDL-C may fall in the transition period.
  • Blood pressure tends to rise; arterial stiffness increases.
  • Body composition shifts toward central adiposity (see Metabolic section).
  • Women’s CVD risk, which lags men’s by ~10 years during reproductive life, converges toward male rates in the post-menopausal decade — see cardiovascular-aging and atherosclerosis 9 6.
  • The Menopause Society / AHA now identify midlife as a critical prevention window for reducing downstream CVD risk 10.

Vasomotor symptoms (hot flashes and night sweats)

The most common and acutely disruptive symptoms of the menopausal transition affect 60–80% of women. The mechanism centers on KNDy neurons (kisspeptin / neurokinin B / dynorphin neurons) in the arcuate nucleus 11:

  • Estrogen normally suppresses KNDy neuronal activity; estrogen withdrawal causes KNDy neuron hypertrophy and hyperactivity.
  • Excess neurokinin B (NKB) signaling via NK3 receptor (NK3R) in the hypothalamus triggers a thermoregulatory flush response — cutaneous vasodilation, sweating, palpitations. no-fulltext-access (Rance 2013 paper closed-access; specific brain region terminology — “preoptic area” vs. “medial preoptic area” vs. other hypothalamic nuclei — could not be verified against the primary text.)
  • The thermoneutral zone narrows severely: small core temperature elevations trigger a flush rather than being buffered.
  • NK3R antagonists (fezolinetant, FDA-approved 2023; elinzanetant in Phase III) are the first non-hormonal mechanism-directed treatment for vasomotor symptoms 12. See vasomotor-symptoms for the KNDy/NK3R mechanism and trial detail.

Night sweats disrupt sleep architecture, contributing to cognitive complaints, fatigue, and metabolic effects.

Genitourinary syndrome of menopause (GSM)

Low estrogen causes progressive atrophy of vulvovaginal and urinary tissues. Estrogen-responsive tissues of the urogenital sinus are highly sensitive to deficiency, producing:

  • Vaginal dryness, dyspareunia, recurrent vulvovaginal infections
  • Urinary urgency, frequency, dysuria, and increased UTI susceptibility
  • Labial/clitoral atrophy

Unlike vasomotor symptoms (which typically improve with time), GSM is chronic and progressive without treatment. It affects ~50% of postmenopausal women and is undertreated due to patient/provider communication gaps. Low-dose local estrogen (ring/cream/tablet) is highly effective with minimal systemic absorption. See genitourinary-syndrome-menopause for mechanism and treatment detail.

Skin: collagen loss and dermal aging

Skin is an estrogen-responsive tissue. After menopause, accelerated skin aging occurs via:

  • Collagen content declines: the earliest published evidence for estrogen’s role in postmenopausal skin collagen comes from Brincat et al. (1983), which found that postmenopausal women treated with estradiol + testosterone implants for 2–10 years had 48% greater skin collagen content (by hydroxyproline assay of 3 mm punch biopsy specimens from the thigh) than untreated controls matched for age (n=26 treated, n=29 untreated; p<0.01) 13. This is a cross-sectional comparison — the paper does not report a 30%-in-5-years loss rate; that widely repeated figure does not originate from this paper and remains unsourced. The Brincat 1983 finding instead shows that long-term hormone therapy is associated with substantially higher collagen content, consistent with accelerated collagen loss after estrogen withdrawal, but the precise post-menopausal collagen loss trajectory and time-course require a longitudinal primary source. needs-verification
  • Dermal thickness decreases: reducing skin strength and healing capacity.
  • Fibroblast activity falls; matrix metalloproteinase (MMP) activity rises.
  • Estrogen therapy demonstrably increases collagen content, dermal thickness, and skin elasticity in postmenopausal women; topical estrogen compounds are an option 14 15.
  • For the full skin-aging picture see skin-aging.

Metabolic: central fat redistribution and insulin resistance

Estrogen modulates fat distribution through ERα signaling in adipocytes. Estrogen withdrawal produces:

  • Preferential accumulation of visceral/central fat (waist circumference increases independently of weight gain in many women).
  • Declining lean mass — compounding the muscle loss trajectory toward sarcopenia.
  • Elevated insulin resistance and worsening glucose tolerance; increased risk of progressing to type 2 diabetes 16.
  • These changes cluster with the cardiovascular risk trajectory above.

Cognitive: neuroprotection and the perimenopausal window

17β-estradiol has documented neuroprotective actions: it promotes synaptic plasticity, supports mitochondrial function in neurons, modulates acetylcholine and serotonin systems, and reduces amyloid-β accumulation 17:

  • Female bias in Alzheimer’s disease (AD): Women represent ~65% of AD cases globally; this cannot be explained by longevity differences alone. Middle-aged women show accelerated AD biomarker accumulation relative to same-age men, coinciding with the perimenopausal window.
  • The “perimenopausal window” hypothesis (Brinton / Mosconi group): the transition period — with fluctuating and ultimately falling estradiol — is the critical interval when neurological vulnerability is established. Brain imaging shows perimenopausal women have altered mitochondrial function and glucose metabolism in AD-relevant regions relative to premenopausal and postmenopausal groups.
  • Early surgical menopause (bilateral oophorectomy) is associated with ~1.5–2× increased risk of dementia and cognitive impairment, supporting a causal role for estrogen in brain aging 18.
  • The perimenopausal window hypothesis remains a subject of active investigation — see alzheimers-disease for the full AD picture. needs-replication

Surgical vs natural menopause

Bilateral oophorectomy (surgical removal of both ovaries) causes abrupt, complete estrogen withdrawal, unlike the gradual menopausal transition. It is used as a natural experiment exposing the downstream consequences of estrogen loss:

  • In women who underwent hysterectomy with bilateral oophorectomy before age 50 and did not use MHT, the inverse-probability-weighted hazard ratio for all-cause mortality compared to women with no hysterectomy who also did not use MHT was 1.81 (95% CI 1.01–3.25) in a 21.5-year Australian cohort study (n=13,541; median follow-up 21.5 years) 19. Critically, this elevated mortality risk was not observed among MHT users after bilateral oophorectomy (IPW HR 0.91; 95% CI 0.67–1.24) and was not observed in the overall bilateral oophorectomy group regardless of MHT use (IPW HR 1.02; 95% CI 0.78–1.34). The mortality signal is therefore confined to the non-MHT-using, pre-menopausal oophorectomy subgroup.
  • Excess risks include cardiovascular disease, osteoporosis, cognitive impairment, and parkinsonism 18.
  • Hormone therapy use appeared to substantially attenuate these risks when initiated promptly post-surgery — consistent with the “timing hypothesis” for MHT.
  • This surgical model underscores the causal (not merely correlational) role of estrogen withdrawal in multi-system aging acceleration.

Ovarian aging mechanisms

The molecular biology of ovarian aging parallels the hallmarks-of-aging framework 20:

  • genomic-instability — oocyte aneuploidy rises dramatically with age due to cohesin degradation on chromosomes (cohesion fatigue). The “limited oocyte model” means quality, not just quantity, falls with age. DNA damage accumulates in oocytes over decades.
  • stem-cell-exhaustion — primordial follicles are a finite non-renewable pool, established in fetal life. Depleted follicle numbers define the FMP.
  • altered-intercellular-communication — declining inhibin B/AMH directly alters pituitary FSH output; declining estradiol alters hypothalamic GnRH pulsatility; the endocrine cascade propagates system-wide.
  • Telomere shortening, reactive oxygen species accumulation, and mitochondrial dysfunction in oocytes also contribute to declining oocyte quality — consistent with telomere-attrition and mitochondrial-dysfunction.

Intervention: menopausal hormone therapy (MHT)

Menopausal hormone therapy (MHT / HRT) is the most effective treatment for vasomotor symptoms and prevents the accelerated bone loss of menopause. For a full treatment page, see hormone-replacement-therapy (stub — needs seeding).

The timing hypothesis: The WHI trials (2002 publication) initially caused widespread MHT discontinuation after showing elevated CVD and breast cancer risk — but the enrolled women were predominantly 60+ years old, many years post-menopause. Re-analysis and the KRONOS Early Estrogen Prevention Study (KEEPS) and Danish Osteoporosis Prevention Study (DOPS) established the timing hypothesis: MHT begun in early menopause (within 10 years of FMP or under age 60) has a favorable cardiovascular risk-benefit profile, whereas initiation in women with established subclinical atherosclerosis may be harmful 21 22 23.

  • Early initiation: associated with ~30% reduction in CHD incidence and all-cause mortality in observational analyses; coronary artery calcification progression reduced in the ELITE trial (oral estradiol started within 6 years of FMP).
  • Late initiation (>10 years post-FMP): no CHD benefit; possibly increased risk — arteries are already less responsive and more atherosclerotic.
  • Breast cancer: combined estrogen-progestogen MHT is associated with a modest increase in breast cancer risk with prolonged use; estrogen-only (for hysterectomized women) carries less or no excess risk depending on the formulation and duration.
  • The Menopause Society (2022) and NICE (UK) guidelines now recommend individualized MHT for symptom management and prevention in eligible women within the timing window, reversing the post-WHI overcorrection.

NK3R antagonists (fezolinetant, elinzanetant): non-hormonal alternatives targeting the KNDy pathway; effective for vasomotor symptoms without sex-hormone exposure 12.

Evolutionary framing

Menopause is unusual in animal biology: only humans (and killer whales and short-finned pilot whales) exhibit reproductive cessation well before somatic death. Most female mammals remain fertile until near death.

Grandmother hypothesis: Proposed that post-reproductive women increase inclusive fitness by provisioning grandchildren, shifting evolutionary benefit from direct reproduction to kin investment. Formalized by Kristen Hawkes et al. in the 1990s–2000s; reanalyzed by Watkins (2021) 24 and challenged empirically by van Bodegom et al. (2010) 25. The hypothesis is contested as a sole explanation — the strength of grandmothering effects on grandchild survival depends heavily on the specific ancestral demographic model, and paternity uncertainty is a key variable. contradictory-evidence

Alternative explanations include: mother-offspring conflict over reproductive investment, oocyte quality senescence making late reproduction too costly (high aneuploidy risk with advanced maternal age), and the “somatic preservation” trade-off (ceasing costly reproduction extends somatic survival, enabling kin investment). These are not mutually exclusive.

No dedicated hypothesis page for menopause evolution currently exists in this wiki. See hypotheses directory; the disposable-soma-theory and antagonistic-pleiotropy frameworks are partially relevant.

Extrapolation to model organisms

DimensionStatus
Pathway conserved in other mammals?Partial — follicle depletion is universal; true menopause (post-reproductive lifespan) rare (killer whales, pilot whales, humans)
Oocyte aneuploidy with age conserved?Yes — documented in mouse, but murine reproductive decline is faster and complete; shorter reproductive lifespan
Downstream estrogen-withdrawal effects in mouse models?Yes for bone/CVD — ovariectomized (OVX) mouse is the standard preclinical model for postmenopausal osteoporosis; some metabolic effects well-modeled; brain aging/AD effects less clear
Replicated in humans?Yes for primary endocrinology; systemic downstream effects are human epidemiological observations

Key caveat: OVX models use abrupt surgical castration, approximating surgical menopause — not the gradual hormonal transition of natural menopause. The progressive KNDy neuronal changes, the “timing hypothesis” cardiovascular window, and the perimenopausal cognitive vulnerability are less well-captured by OVX.

Limitations and gaps

  • The “timing hypothesis” quantification remains incomplete: no large RCT has randomized women to early vs late MHT initiation specifically powered for coronary endpoints. The ELITE, KEEPS, and DOPS trials were underpowered; the DELPHI trial is ongoing. needs-replication
  • Perimenopausal window hypothesis (brain): the hypothesis that the perimenopausal transition specifically (not just postmenopause) is the critical vulnerability window remains to be tested in a prospective RCT. Cross-sectional neuroimaging data are consistent but not causal. needs-replication
  • Collagen loss quantification: the widely cited “~30% collagen loss in first 5 years” figure is not supported by the Brincat 1983 BMJ paper (doi:10.1136/bmj.287.6402.1337), which was a cross-sectional HRT vs. no-HRT comparison (48% greater collagen in treated women), not a longitudinal loss-rate measurement. A primary longitudinal source for the post-menopausal collagen loss trajectory and time-course has not been identified. needs-verification unsourced
  • POI management: no RCT data exist for MHT in POI patients with end-points of cardiovascular or cognitive outcomes — observational data only.
  • Male analogue (andropause): the male counterpart (gradual testosterone decline, no sharp reproductive cessation) is not addressed here; see testosterone and planned andropause page. stub
  • Ethnicity and timing: age at FMP varies by ethnic background (Black and Latina women tend to transition earlier in some cohorts; Japanese women later). STRAW+10 criteria are cross-population, but downstream risk magnitudes may differ.
  • Transgender and non-binary individuals: exogenous hormone regimens alter the relationship between ovarian function and systemic estrogen; not addressed here.

Hallmark mapping

HallmarkMenopause role
stem-cell-exhaustionPrimordial follicle pool depletion is the direct cause of the FMP; this is stem-cell exhaustion at the gametic level
altered-intercellular-communicationEstrogen withdrawal disrupts paracrine/endocrine signals to bone, brain, vasculature, and skin — the broadest endocrine aging signal in human biology
genomic-instabilityOocyte aneuploidy from cohesin degradation; DNA damage accumulation over reproductive lifespan
telomere-attritionTelomere shortening in oocytes contributes to declining quality
mitochondrial-dysfunctionMitochondrial decline in oocytes and postmenopausal tissues
chronic-inflammationEstrogen has anti-inflammatory properties; postmenopause associated with rise in inflammatory markers — see chronic-inflammation
cellular-senescenceSenescent granulosa cells may contribute to ovarian aging microenvironment (emerging evidence; understudied)

Cross-references

Footnotes

Footnotes

  1. doi:10.1210/jc.2011-3362 · Harlow SD et al. (STRAW+10 Collaborative Group) · J Clin Endocrinol Metab 2012;97(4):1159–1168 · simultaneously published as doi:10.1097/gme.0b013e31824d8f40 (Menopause 2012; PMC3319184) · consensus framework for staging reproductive aging in women; 10 stages (−5 through +2) anchored on FMP (Stage 0); early postmenopause subdivided into +1a (year 1), +1b (year 2), +1c (years 3–8 approx.); FSH >25 IU/L on random blood draw defines Stage −1 late transition; FSH, AMH, inhibin B, AFC as supportive criteria; applicable regardless of age, ethnicity, BMI, or lifestyle; 41 scientists from 5 countries; seven research priorities identified · model: expert consensus on human cohort data (SWAN, Melbourne Women’s Midlife Health Project, ReSTAGE, others) ↩ ↩2

  2. doi:10.1097/GME.0000000000000235 · Jaff NG, Snyman T, Norris SA, Crowther NJ · Menopause 2014;21(11):1249–1257 · STRAW+10 validated in Black South African women; FSH and estradiol correlated with menopausal transition phase; higher BMI associated with more severe vasomotor symptoms · model: human observational ↩

  3. doi:10.1016/j.jsbmb.2013.08.015 · Hale GE, Robertson DM, Burger HG · J Steroid Biochem Mol Biol 2014;142:121–129 · review of perimenopausal endocrinology; ovarian follicle reserve decline, inhibin B fall as earliest marker, FSH rise, irregular anovulatory cycles; STRAW staging incorporated ↩

  4. PMID 21178920 · Su HI · Minerva Endocrinologica 2011;36(1):1–11 · review of ovarian reserve tests; FSH, AMH, and AFC as most sensitive markers; AMH linearly tracks follicle pool size; validated in multiple clinical populations ↩

  5. doi:10.20471/acc.2016.55.04.14 · Franić-Ivanišević M et al. · Acta Clin Croat 2016;55(4):601–608 · genetics of primary POI; prevalence 1:10,000 at 18–25 yr; 1:100 at 35–40 yr; FSH ≥25 IU/L + low estradiol as diagnostic threshold; ~15% have positive family history; genetic etiologies include Turner syndrome, FMR1 premutation, FOXL2 ↩

  6. doi:10.1016/S2213-8587(22)00076-6 · Nappi RE, Chedraui P, Lambrinoudaki I, Simoncini T · Lancet Diabetes Endocrinol 2022;10(6):442–456 · menopause as cardiometabolic transition; endogenous estrogen provides CVD protection during reproductive years lost ~10 years post-menopause; vasomotor symptoms associated with unfavorable cardiometabolic profile; review ↩ ↩2

  7. doi:10.1016/j.cytogfr.2020.02.003 · Li J, Chen X, Lu L, Yu X · Cytokine Growth Factor Rev 2020;52:43–55 · bone marrow adipose tissue expansion in postmenopausal osteoporosis; osteoblast/adipocyte common progenitor lineage; adipokines and cytokines from marrow adipocytes suppress osteoblast activity; estrogen withdrawal disinhibits adipogenic differentiation ↩

  8. doi:10.4103/ijmr.IJMR_524_18 · Bonaccorsi G, Piva I, Greco P, Cervellati C · Indian J Med Res 2018;147(4):341–351 · estrogen deficiency → redox imbalance → oxidative stress → osteoclast activation and bone loss; mechanistic review ↩

  9. doi:10.1161/CIR.0000000000000912 · El Khoudary SR et al. (AHA Scientific Statement) · Circulation 2020;142(25):e506–e532 · CVD the leading cause of mortality in women; adverse cardiometabolic changes across menopausal transition; midlife as critical prevention window; n=large epidemiological meta-analysis ↩

  10. doi:10.1016/j.maturitas.2024.107974 · Uddenberg ER, Safwan N, Saadedine M et al. · Maturitas 2024;183:107974 · CVD risk increases in women’s fifth decade coinciding with menopause — ~decade earlier than comparable male risk; cardiometabolic shifts including central adiposity, BP rise, lipoprotein changes, insulin resistance documented ↩

  11. doi:10.1016/j.yfrne.2013.07.003 · Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ · Front Neuroendocrinol 2013;34(3):211–227 · arcuate KNDy (kisspeptin/NKB/dynorphin) neurons mediate estrogen-dependent thermoregulation; NK3R activation in preoptic nucleus triggers thermoregulatory flush; ablation reduces cutaneous vasodilation; model: rat + human (hypertrophied neurons in postmenopausal women) ↩

  12. doi:10.3390/jcm14051438 · Meczekalski B et al. · J Clin Med 2025;14(5):1438 · review of NK3R antagonists for vasomotor symptoms; fezolinetant FDA-approved 2023; elinzanetant (dual NK-1/NK-3 antagonist) Phase III OASIS trials; restores disrupted KNDy neuron balance caused by estrogen deficiency ↩ ↩2

  13. doi:10.1136/bmj.287.6402.1337 · Brincat M, Moniz CF, Studd JWW et al. · Br Med J 1983;287(6402):1337–1338 · cross-sectional study; n=29 untreated postmenopausal women vs n=26 treated with oestradiol 50 mg + testosterone 100 mg implants (2–10 yr); skin collagen (hydroxyproline; 3 mm punch biopsy, right thigh) 48% greater in treated group (p<0.01); matched for age; does NOT report a “30%-in-5-years loss” rate — this is a cross-sectional HRT vs no-HRT comparison, not a longitudinal loss trajectory · model: human observational (cross-sectional) ↩

  14. doi:10.1007/s13555-020-00468-7 · Lephart ED, Naftolin F · Dermatol Ther (Heidelb) 2021;11(1):53–69 · estrogen deficiency after menopause drives collagen and elastin loss, fibroblast dysfunction, MMP upregulation; phytoestrogens and cosmeceuticals as alternatives; HRT reverses many skin changes; review ↩

  15. doi:10.1258/175404507780796325 · Calleja-Agius J, Muscat-Baron Y, Brincat MP · Menopause Int 2007;13(2):60–64 · collagen atrophy as major factor in skin aging post-menopause; estrogen therapy increases collagen content, dermal thickness, elasticity; historical context of estrogen-collagen research ↩

  16. doi:10.1080/09513590.2021.2004395 · Moccia P, Belda-Montesinos R, Monllor-Tormos A, Chedraui P, Cano A · Gynecol Endocrinol 2022;38(2):103–111 · menopausal transition increases visceral fat accumulation; declining lean mass; ERα dysfunction and androgen-estrogen imbalance as primary drivers; insulin resistance documented ↩

  17. doi:10.3389/fnagi.2022.948219 · Jett S, Schelbaum E, Jang G et al. (Mosconi L, Brinton RD groups) · Front Aging Neurosci 2022;14:948219 · 17β-estradiol neuroprotection: synaptic plasticity, mitochondrial function, cholinergic/serotonergic modulation, amyloid-β; perimenopausal women show accelerated AD biomarkers vs same-age men; female AD prevalence ~double men; perimenopausal window as critical vulnerability; human neuroimaging + mechanistic review ↩

  18. doi:10.1258/mi.2008.008016 · Shuster LT, Gostout BS, Grossardt BR, Rocca WA · Menopause Int 2008;14(3):111–116 · prophylactic oophorectomy in premenopausal women → increased risk of premature death, CVD, cognitive impairment/dementia, parkinsonism, osteoporosis; estrogen treatment partially but not fully prevents adverse outcomes; observational evidence ↩ ↩2

  19. doi:10.1016/j.ajog.2018.10.002 · Wilson LF, Pandeya N, Byles J, Mishra GD · Am J Obstet Gynecol 2019;220(5):83.e1–83.e11 · Australian Longitudinal Study on Women’s Health (ALSWH); n=13,541 women born 1946–1951; median follow-up 21.5 years; 901 deaths; inverse-probability-weighted Cox models; hysterectomy-bilateral oophorectomy before age 50 without MHT vs no hysterectomy without MHT → IPW HR 1.81 (95% CI 1.01–3.25); overall bilateral oophorectomy group (all MHT strata combined) → IPW HR 1.02 (95% CI 0.78–1.34, not significant); MHT use attenuated excess risk in oophorectomy group; ovarian conservation without MHT not associated with higher mortality (IPW HR 0.93; 95% CI 0.75–1.17) · model: human observational (prospective cohort) ↩

  20. doi:10.1530/REP-21-0022 · Park SU, Walsh L, Berkowitz KM · Reproduction 2021;162(2):R19–R33 · review of molecular mechanisms of ovarian aging; cohesin degradation → oocyte aneuploidy; DNA damage accumulation; telomere shortening; ROS; mitochondrial dysfunction; protein homeostasis failure; model: human + rodent ↩

  21. doi:10.1210/endrev/bnab011 · Flores VA, Pal L, Manson JE · Endocr Rev 2021;42(6):764–779 · comprehensive MHT review; risk-benefit ratio varies markedly by age and time since menopause; WHI younger women (50–59) showed favorable CHD and mortality effects; timing hypothesis framing; moderate-to-severe symptoms + absence of contraindications → appropriate candidates ↩

  22. doi:10.1016/j.metabol.2016.01.004 · Bassuk SS, Manson JE · Metabolism 2016;65(5):621–629 · timing hypothesis: estrogen beneficial for heart if started in early menopause when arteries healthy; potentially harmful if initiated later with established atherosclerosis; re-analysis of WHI + HERS data by age stratum ↩

  23. doi:10.1016/j.pcad.2024.01.015 · Gersh F, O’Keefe JH, Elagizi A, Lavie CJ, Laukkanen JA · Prog Cardiovasc Dis 2024;84:23–31 · cardioprotective role of estradiol in reproductive-age women; timing hypothesis supported; early post-cessation HRT initiation recommended; review ↩

  24. doi:10.1007/s40656-021-00455-x · Watkins A · Hist Philos Life Sci 2021;43(4):120 · formal model of grandmother hypothesis; paternity uncertainty key variable; conditions under which grandmother > grandfather contribution; contested but mathematically formalizable ↩

  25. doi:10.1159/000255170 · van Bodegom D, Rozing M, May L et al. · Gerontology 2010;56(2):210–216 · critical commentary on grandmother hypothesis; low female survival to post-reproductive ages in ancestral populations weakens hypothesis; grandmothering effects on grandchild survival limited in historical populations ↩

Graph View

Backlinks